Lacktman Quoted on New Coverage for Virtual Check-Ins
November 5, 2018
mHealth Intelligence
Partner Nate Lacktman was quoted in an mHealth Intelligence article, “CMS Gives Telehealth a Nudge With Coverage for Virtual Check-Ins,” about the Centers for Medicare & Medicaid Services’ approval of a new code giving providers an opportunity to use telehealth to check in with their patients on care management issues.
Lacktman said the new code represents a “sizeable change” to allow providers to efficiently use new technologies to deliver medical care. “By reimbursing for virtual check-ins, the new code exemplifies CMS’ renewed vision and desire to bring the Medicare program into the future of clinically-valid virtual care services,” he said.
Lacktman said the new code represents a “sizeable change” to allow providers to efficiently use new technologies to deliver medical care. “By reimbursing for virtual check-ins, the new code exemplifies CMS’ renewed vision and desire to bring the Medicare program into the future of clinically-valid virtual care services,” he said.
People
Related News
September 18, 2026
In the News
Patrick Daugherty Authors Article on Navigating Proposed SEC Crypto Asset Regulations
Foley & Lardner LLP partner Patrick Daugherty authored the Columbia Law School’s Blue Sky Blog article, “How to Advise Token Developers in Light of Proposed SEC Regulation Crypto Assets.”
September 17, 2026
In the News
Foley Featured in Law.com for Guiding Kontoor Brands in Sale of Lee®
Foley & Lardner LLP partner Bryan Schultz is featured for leading the Foley deal team which advised Kontoor Brands in the sale of its Lee® business in Law.com's “How the Deal Got Done” series.
September 15, 2026
In the News
David Rosen Shares Insights on FDA Efforts to Accelerate Human Clinical Trials
Foley & Lardner LLP partner David Rosen shared insights in the recent Law360 article, “FDA Seeks Applications For Project To Speed Up Human Trials,” on the FDA's pilot program pairing pharmaceutical companies with research institutions to accelerate human clinical trials.